Vanguard Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-4,157,552
| Closed | -$313M | – | 4638 |
|
|
2022
Q2 | $313M | Buy |
4,157,552
+244,424
| +6% | +$10.9M | 0.01% | 1147 |
|
|
2022
Q1 | $105M | Buy |
3,913,128
+35,789
| +0.9% | +$1.2M | ﹤0.01% | 1908 |
|
|
2021
Q4 | $185M | Buy |
3,877,339
+10,002
| +0.3% | +$447K | ﹤0.01% | 1660 |
|
|
2021
Q3 | $257M | Buy |
3,867,337
+165,770
| +4% | +$11.8M | 0.01% | 1442 |
|
|
2021
Q2 | $289M | Buy |
3,701,567
+9,027
| +0.2% | +$667K | 0.01% | 1388 |
|
|
2021
Q1 | $349M | Buy |
3,692,540
+252,080
| +7% | +$30M | 0.01% | 1206 |
|
|
2020
Q4 | $419M | Buy |
3,440,460
+563,000
| +20% | +$61.7M | 0.01% | 976 |
|
|
2020
Q3 | $251M | Buy |
2,877,460
+94,277
| +3% | +$6.57M | 0.01% | 1126 |
|
|
2020
Q2 | $180M | Buy |
2,783,183
+695,062
| +33% | +$40.1M | 0.01% | 1334 |
|
|
2020
Q1 | $93.3M | Buy |
2,088,121
+122,887
| +6% | +$6.53M | ﹤0.01% | 1568 |
|
|
2019
Q4 | $122M | Buy |
1,965,234
+1,242,668
| +172% | +$59.1M | ﹤0.01% | 1660 |
|
|
2019
Q3 | $27.2M | Buy |
722,566
+287,386
| +66% | +$12.5M | ﹤0.01% | 2325 |
|
|
2019
Q2 | $17.7M | Buy |
+435,180
| New | +$15.5M | ﹤0.01% | 2575 |
|
Vanguard Group's TPTX Position: Q3 2022 in Review
Vanguard Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,157,552 shares — an estimated $313M sold.
Vanguard Group first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $419M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Vanguard Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Vanguard Group sold 4,157,552 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $313M.
- Vanguard Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Vanguard Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $419M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.